Ionis Pharmaceuticals Inc
IONS81.680USD
-0.130-0.16%
Cierre 12/05, 16:00（ET）Cotizaciones retrasadas 15 min
13.16BCap. mercado
PérdidaP/E TTM
Más Datos de Ionis Pharmaceuticals Inc Compañía
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Información de Ionis Pharmaceuticals Inc
Símbolo de cotizaciónIONS
Nombre de la empresaIonis Pharmaceuticals Inc
Fecha de salida a bolsaMay 17, 1991
Director ejecutivoDr. Brett P. Monia, Ph.D.
Número de empleados1069
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 17
Dirección2855 Gazelle Court
CiudadCARLSBAD
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92010
Teléfono17609319200
Sitio Webhttps://www.ionis.com/
Símbolo de cotizaciónIONS
Fecha de salida a bolsaMay 17, 1991
Director ejecutivoDr. Brett P. Monia, Ph.D.
Ejecutivos de Ionis Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-0.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-5.67%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-14.08%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
30.57K
-18.30%
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.49K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-0.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-5.67%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-14.08%
Desglose de ingresos
Divisa: USDActualizado: mar., 4 de mar
Divisa: USDActualizado: mar., 4 de mar
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Estadísticas de accionistas
Actualizado: mié., 19 de nov
Actualizado: mié., 19 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.63%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
Capital World Investors
7.85%
BlackRock Institutional Trust Company, N.A.
5.22%
Otro
54.02%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.63%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
Capital World Investors
7.85%
BlackRock Institutional Trust Company, N.A.
5.22%
Otro
54.02%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
68.63%
Investment Advisor/Hedge Fund
19.49%
Hedge Fund
13.84%
Research Firm
2.62%
Pension Fund
1.04%
Bank and Trust
0.81%
Individual Investor
0.75%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
23.64M
14.83%
+29.41K
+0.12%
Jun 30, 2025
The Vanguard Group, Inc.
16.68M
10.47%
+329.29K
+2.01%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.05M
10.07%
-126.81K
-0.78%
Jun 30, 2025
Capital World Investors
12.54M
7.87%
+178.19K
+1.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.73M
5.47%
-171.64K
-1.93%
Jun 30, 2025
Wellington Management Company, LLP
6.35M
3.98%
-2.07M
-24.60%
Jun 30, 2025
Bellevue Asset Management AG
7.85M
4.93%
--
--
Jun 30, 2025
State Street Investment Management (US)
4.53M
2.84%
-314.74K
-6.50%
Jun 30, 2025
Deep Track Capital LP
4.89M
3.07%
+327.34K
+7.17%
Jun 30, 2025
Two Sigma Investments, LP
4.46M
2.8%
+678.11K
+17.95%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: hace 23 horas
Actualizado: hace 23 horas
Nombre
Proporción
Invesco Biotechnology & Genome ETF
5.24%
ARK Genomic Revolution ETF
4.11%
Virtus LifeSci Biotech Products ETF
3.34%
Franklin Genomic Advancements ETF
2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.57%
First Trust Health Care Alphadex Fund
2.47%
VanEck Morningstar SMID Moat ETF
2.38%
WisdomTree BioRevolution Fund
2.28%
State Street SPDR S&P Biotech ETF
2.28%
Capital Group US Small and Mid Cap ETF
2.04%
Ver más
Invesco Biotechnology & Genome ETF
Proporción5.24%
ARK Genomic Revolution ETF
Proporción4.11%
Virtus LifeSci Biotech Products ETF
Proporción3.34%
Franklin Genomic Advancements ETF
Proporción2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción2.57%
First Trust Health Care Alphadex Fund
Proporción2.47%
VanEck Morningstar SMID Moat ETF
Proporción2.38%
WisdomTree BioRevolution Fund
Proporción2.28%
State Street SPDR S&P Biotech ETF
Proporción2.28%
Capital Group US Small and Mid Cap ETF
Proporción2.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Ionis Pharmaceuticals Inc?
Los cinco principales accionistas de Ionis Pharmaceuticals Inc son:
Fidelity Management & Research Company LLC posee 23.64M acciones, lo que representa el 14.83% del total de acciones.
The Vanguard Group, Inc. posee 16.68M acciones, lo que representa el 10.47% del total de acciones.
T. Rowe Price Investment Management, Inc. posee 16.05M acciones, lo que representa el 10.07% del total de acciones.
Capital World Investors posee 12.54M acciones, lo que representa el 7.87% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 8.73M acciones, lo que representa el 5.47% del total de acciones.
Fidelity Management & Research Company LLC posee 23.64M acciones, lo que representa el 14.83% del total de acciones.
The Vanguard Group, Inc. posee 16.68M acciones, lo que representa el 10.47% del total de acciones.
T. Rowe Price Investment Management, Inc. posee 16.05M acciones, lo que representa el 10.07% del total de acciones.
Capital World Investors posee 12.54M acciones, lo que representa el 7.87% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 8.73M acciones, lo que representa el 5.47% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Ionis Pharmaceuticals Inc?
Los tres principales tipos de accionista de Ionis Pharmaceuticals Inc son:
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
¿Cuántas instituciones poseen acciones de Ionis Pharmaceuticals Inc (IONS)?
A fecha de 2025Q3, 815 instituciones poseen acciones de Ionis Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 172.95M, lo que representa el 106.78% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -9.56%.
¿Cuál es la mayor fuente de ganancias de Ionis Pharmaceuticals Inc?
El FY2020, el segmento empresarial R&D revenue under collaborative agreements generó la ganancia más alta para Ionis Pharmaceuticals Inc, ascendiendo a 364.56M y representando el 49.99% de la ganancia total.
